18th ICID | International Congress on Infectious Diseases, Buenos Aires, Argentina
Abstract Guidelines
Abstract Deadline extended to November 9, 2017!

General Information | Electronic Submission


General Information:

  • Download Spanish guidelines here.
  • All abstracts for the 18th ICID and XVIII Congreso SADI must be submitted electronically through the electronic abstract submission system. Click here to access the online submission system.
  • All abstracts must be submitted in English. You can indicate if you wish to do your actual presentation in English or Spanish.
  • Abstracts accepted for oral presentation can be presented in English (during the 18th ICID, March 2, 3, or 4) or in Spanish (during the XVIII Congreso SADI, March 1). Preferred presentation language must be indicated at the time of abstract submission.
  • All abstracts must be received on or before November 3, 2017 (extended to November 9, 2017)
  • Abstract acceptance notifications will be sent by December 15, 2017.
  • Based on previous ICID's, more than 800 abstracts will be presented during the congress. Eighty reviewers from more than 30 countries are reviewing and scoring abstracts.
  • Only highest scored accepted abstracts will be published as an online supplement to the International Journal for Infectious Diseases (IJID).

Abstract submission information:

  • All abstracts have a 350 word limit of text (not including presenter information and title) and should be in one of the following categories:

  • Abstract Topics:
    • Animal Models, Pathogenesis and Host Defenses
    • Antimicrobial Resistance
    • Antimicrobials: Adherence and Stewardship
    • Antimicrobials: Clinical Trials
    • Antimicrobials: Mechanisms and Spectrum
    • Antimicrobials: Pharmacology
    • Bacterial Infections
    • Diagnostics
    • Economics, Health Policy and Implementation
    • Emerging Infectious Diseases
    • Epidemiology and Public Health
    • HIV/AIDS and Other Retroviruses
    • Immunocompromised Host (Non-HIV)
    • Infection Control
    • Nosocomial Infections and Critical Care
    • Infectious Disease Surveillance and Notification
    • Mycology, Fungal Infections and Antifungal Drugs
    • Parasitology and Parasitic Infections
    • Pediatric and Perinatal Infections
    • Geriatric Infections
    • Sexually Transmitted Diseases
    • Travel Medicine and Travel Health
    • Tuberculosis and Other Mycobacterial Infections
    • Vaccines and Vaccine Development
    • Virology and Viral Infections (Non-HIV)
    • Zoonoses and Infections in Animals
    • Other

  • Submitting authors are required to ensure that all listed co-authors have reviewed the abstract, take responsibility for its content and agree with being listed as co-author.
  • All potential conflicts of interest for each co-author must be provided. Potential conflicts of interest include, but are not limited to, commercial interest in the research, and financial or in-kind support for the research, and financial or in-kind support for the research from entities with commercial interest in research.
  • Each abstract will be reviewed and scored by two members of the 18th ICID/XVIII Congreso SADI review committee for the quality and originality of the research, the scientific content and presentation. A notice of acceptance or rejection will be sent to the submitting authors only. It is the responsibility of the submitting author to notify other co-authors of the Committee's decision. Session assignments will be mailed by December 15, 2017 to the address given for correspondence.
  • The abstract review process is blinded, meaning that the authors' names and affiliations are not disclosed to the reviewers.
  • Authors are encouraged to submit their abstracts as early as possible.
  • Acceptance of the abstract in the program and assignment to a session are determined solely by the Program Committee based on the abstract's subject matter and combined reviewer scores and comments. Decisions of the Program Committee are final. Because of the logistics of assigning abstracts to sessions and the number of abstracts received, requests for particular types of presentations, sessions, days, or times will not be considered by the Program Committee.
  • All presenters of accepted abstracts must be registered and attend the 18th ICID in order to have the abstract published in the online supplement to the International Journal of Infectious Diseases (IJID).
  • All accepted abstracts will be published in the supplement to the IJID as is.
  • By submitting an abstract the author(s) agree to transfer all copyrights to ISID and to allow publication of submitted information on the ISID web site, the International Journal of Infectious Diseases (IJID) or other Society related publications.
  • Instructions will be sent to the authors whose abstracts are accepted for oral or poster presentation. For each abstract accepted for presentation, at least one author must attend the Congress and present the contribution.
  • If the registration fee of the presenting author is not received by January 31, 2018 the abstract will not be published in the Final Program.

Abstracts may be accepted into one of three categories:

  • Oral presentation: The presenting author will be required to make a 7 minute Powerpoint presentation that concisely summarizes the research question, the methods used, the results and their significance. Abstracts accepted for oral presentation will be published as an online supplement to the International Journal of Infectious Diseases (IJID).
  • Moderated poster presentation: The presenting author will be obliged to present the poster during the moderated poster session to which it has been assigned. Abstracts accepted for moderated poster presentation will be published as an online supplement to the International Journal of Infectious Diseases (IJID) and distributed to congress participants on site.
  • Electronic poster presentation: Abstracts accepted into this category will be available for viewing on computer terminals at the ICID. Abstracts accepted for electronic poster presentation will be published as an online supplement to the International Journal of Infectious Diseases (IJID).
  • Presenters who do not attend the session for which they have been scheduled will be ineligible to submit an abstract for the next ICID. Those abstracts will not be published in the International Journal for Infectious Diseases.

return to top

The Program Committee has outlined the following guidelines for developing an abstract:

  • Abstracts must be based on original results that have not or will not be published or presented before the 18thICID/XVIII Congreso SADI begins on March 1, 2018.
  • It is recommended that abstracts follow the format below:
    • Background: A statement of the hypothesis or research question.
    • Methods & Materials: An explanation of the study design and experimental method and materials used.
    • Results: A concise summary of the major findings of the experiment or study. Sufficient data must be provided to permit evaluation by the reviewers and public reading of the abstracts. Statements such as "additional information to be presented at the meeting" are not acceptable.
    • Conclusion: Summary of the overall findings and the importance of the study
      • DO NOT repeat these section headers in your abstract body! Do not format the complete abstract in bold or italic letters!
    • Abstracts that represent the presentation of single clinical cases of previously reported diseases, investigations of compounds that involve inadequate numbers of study subjects, or in vitro studies of non-representative microbiologic strains, or abstracts that lack quantitative or qualitative data will not be accepted. Authors are discouraged from submitting multiple abstracts from the same project. Each abstract will be judged on its own merits without reference to other submissions. Repetitive abstracts will be rejected.

Online Abstract Submission:

  • Click here to access the online submission system.

Should you require further explanation, send an e-mail to info@isid.org or call ISID at (617) 277–0551.

return to top